Abivax (NASDAQ:ABVX - Get Free Report) had its price target hoisted by investment analysts at Guggenheim from $50.00 to $101.00 in a research note issued on Wednesday,Benzinga reports. The firm presently has a "buy" rating on the stock.
A number of other analysts also recently commented on ABVX. Citigroup reissued a "market outperform" rating on shares of Abivax in a research note on Friday. Morgan Stanley upgraded shares of Abivax from an "equal weight" rating to an "overweight" rating and set a $71.00 target price on the stock in a report on Wednesday. Finally, JMP Securities upped their price target on Abivax from $33.00 to $95.00 and gave the company a "market outperform" rating in a report on Wednesday. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $78.75.
Read Our Latest Stock Analysis on ABVX
Abivax Price Performance
ABVX stock opened at $10.00 on Wednesday. Abivax has a 52 week low of $4.77 and a 52 week high of $62.22. The firm's 50-day moving average is $7.14 and its two-hundred day moving average is $6.80. The company has a debt-to-equity ratio of 1.29, a quick ratio of 1.25 and a current ratio of 1.25.
Institutional Inflows and Outflows
Several hedge funds have recently modified their holdings of the business. Two Sigma Investments LP acquired a new position in shares of Abivax during the 4th quarter valued at about $144,000. JPMorgan Chase & Co. acquired a new position in Abivax in the 4th quarter valued at $5,336,000. GAMMA Investing LLC grew its position in shares of Abivax by 373.6% in the first quarter. GAMMA Investing LLC now owns 18,831 shares of the company's stock valued at $118,000 after purchasing an additional 14,855 shares during the last quarter. Guggenheim Capital LLC acquired a new stake in shares of Abivax in the fourth quarter valued at about $92,000. Finally, Millennium Management LLC grew its holdings in Abivax by 44.2% in the 4th quarter. Millennium Management LLC now owns 931,179 shares of the company's stock valued at $6,816,000 after buying an additional 285,542 shares during the last quarter. Institutional investors and hedge funds own 47.91% of the company's stock.
About Abivax
(
Get Free Report)
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Abivax, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abivax wasn't on the list.
While Abivax currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
